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http://www.biomedcentral.com/1471-2474/14/318RESEARCH ARTICLE Open AccessDevelopment of a new pre-vascularized
tissue-engineered construct using
pre-differentiated rADSCs, arteriovenous
vascular bundle and porous
nano-hydroxyapatide-polyamide 66 scaffold
Pei Yang1, Xin Huang2, Jacson Shen3, Chunsheng Wang1, Xiaoqian Dang1, Henry Mankin4,5, Zhenfeng Duan4,5
and Kunzheng Wang1*Abstract
Background: Development of a pre-vascularized tissue-engineered construct with intrinsic vascular system for cell
growth and tissue formation still faces many difficulties due to the complexity of the vascular network of natural
bone tissue. The present study was to design and form a new vascularized tissue-engineered construct using
pre-differentiated rADSCs, arteriovenous vascular bundle and porous nHA-PA 66 scaffold.
Methods: rADSCs were pre-differentiated to endothelial cells (rADSCs-Endo) and then incorporated in nHA-PA 66
scaffolds in vitro. Subsequently, in vivo experiments were carried out according to the following groups: Group A
(rADSCs-Endo/nHA-PA 66 scaffold with arteriovenous vascular bundle), Group B (rADSCs/nHA-PA 66 scaffold with
arteriovenous vascular bundle); Group C (nHA-PA66 scaffold with arteriovenous vascular bundle), Group D (nHA-PA
66 scaffold only). The vessel density and vessel diameter were measured based on histological and
immunohistochemical evaluation, furthermore, the VEGF-C, FGF-2 and BMP-2 protein expressions were also
evaluated by western blot analysis.
Results: The results of in vivo experiments showed that the vessel density and vessel diameter in group A were
significantly higher than the other three groups. Between Group B and C, no statistical difference was observed at
each time point. In accordance with the results, there were dramatically higher expressions of VEGF-C and FGF-2
protein in Group A than that of Group B, C and D at 2 or 4 weeks. Statistical differences were not observed in
VEGF-C and FGF-2 expression between Group B and C. BMP-2 was not expressed in any group at each time point.
Conclusions: Compared with muscular wrapping method, arteriovenous vascular bundle implantation could
promote vascularization of the scaffold; and the angiogenesis of the scaffold was significantly accelerated when
pre-differentiated rADSCs (endothelial differentiation) were added. These positive results implicate the combination
of pre-differentiated rADSCs (endothelial differentiation) and arteriovenous vascular bundle may achieve rapidly
angiogenesis of biomaterial scaffold.
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Clinically, autologous bone grafting with arteriovenous
vascular bundle implantation has been widely used for
the treatment of avascular necrosis of the femoral head
[1], bone defects [2] and non-union [3,4]. Though the
technique is viewed as the “gold standard” [5] for its
therapeutic safety and efficacy, many complications may
arise such as wound issues, vessel injuries and bleeding
which require a secondary surgical operation [6,7]. This
leads us to propose the development of a pre-vascularized
construct that would provide an intrinsic vascular system
for cell growth and tissue development.
Undoubtedly, tissue-engineered bone and cartilage can
be successful constructed both in vitro and in vivo [8,9].
However, the technique of forming an intrinsic vascular
system within the bone tissue-engineered scaffolds remains
a challenge due to the complexity of the vascular network
of natural bone tissue [10]. Several extensive studies have
been carried out to accelerate the vascularization process
in bone tissue engineering [11]. Compared with other
methods, the application of non-functional pre-existing
blood vessels in vivo as a vascular carrier and incorpor-
ation of biomaterials and cells or growth factors into them
is advantageous, as it allows for instantaneous perfusion
after the graft is implanted, which can dramatically de-
crease the time required for capillary ingrowth [10,12-15].
Arteriovenous vascular loop (AV-loop) [10,13,16] and ar-
teriovenous vascular bundle (AV-bundle) [10,15,17] are
recognized as pre-existing blood vessels, which have been
used in animal experiments. Furthermore, AV-bundle has
been used for clinical treatment [1-4]. Theoretically, the
potential mechanisms of accelerated angiogenesis by the
AV-loop and AV-bundle have been proposed as follows
[18]: (1). Inflammatory responses caused by surgical
trauma promote the releasing of inflammatory factors,
which physiologically increase vascular permeability, and
promoted capillary network building; (2). Local matrix
hypoxic conditions lead to the up-regulation of hypoxia
inducible factor (HIF-1) expression and subsequently up-
regulate the expression of angiogenic factors such as vas-
cular endothelial growth factor (VEGF), which results in
cascade amplification to increase vascular permeability
and to stimulate the proliferation of endothelial cells and
maintain the physiological function of its differentiated
state; (3). Vascular flow shear stress (FSS) played an im-
portant role in adult angiogenesis process. High FSS could
promote the growth of collateral vessels whose growth has
stopped, and the number of microvessels has increased
significantly [12,18,19].
Compared with the direct use of angiogenic factors in
the pre-vascularized procedures, the application of an-
giogenic cells may provide a suitable method of con-
tinuous local delivery of angiogenic cytokines through
autocrine/paracrine mechanism for extended periods[16]. Endothelial progenitor cells (EPCs) [20] and human
umbilical vein endothelial cells (HUVECs) [21] have been
previously transplanted into biomaterial scaffolds, demon-
strating that the cells can accelerate angiogenesis. How-
ever, limited sources will hamper their clinical application.
Mesenchymal stem cells isolated from adipose tissue
(ADSCs) demonstrate similar multilineage differentiation
potencies (including endothelial differentiation) with
bone-marrow derived mesenchymal stem cells (BMSCs),
which are widely investigated in bone tissue engineering
[22]. The use of ADSCs rather than BMSCs may be ad-
vantageous in that greater cell numbers can be harvested
from the patient with less pain. As well, ADSCs are re-
ported to have positive effects on patients who received
bone marrow transplantation and suffered from GVHD
(graft versus host disease), suggesting that they have an
immunomodulatory function [23]. These results suggest
that ADSCs may be an attractive cell candidate for the
prefabrication of vascularized construct.As for the bioma-
terials scaffold, the shape of the scaffold must be con-
trolled and customized. Three-dimensional scaffolds made
of biomaterials such as nano-hydroxyapatite-polyamide 66
(nHA-PA 66) have been shown to be an effective compos-
ition material candidate for three-dimensional scaffolds
due to its favorable biocompatibility/chemical composition
osteoconductivity and bioactivity [24-26].
In the present study, rat ADSCs (rADSCs) were pre-
differentiated to endothelial cells, and then incorporated
in nHA-PA 66 scaffolds in vitro. Subsequently, the com-
posites were implanted with or without AV-bundle
in vivo. We hypothesized that rADSCs derived endothe-
lial cells together with AV-bundle would accelerate vas-
cularity of the scaffolds in vivo.
Methods
In vitro experiments
The characteristic of the nHA-PA 66 scaffold
The nHA-PA 66 scaffold was synthesized from nano-
hydroxyapatite and polyamide 66 foamed by the thermal
pressing and the injection molding techniques by Sichuan
Guona Technology Co., Ltd (Chengdu, Sichuan, China).
The biomechanical properties (including elastic modulus,
bending strength and compressive strength) and porosity
were tested according to the methods reported previously
[27] (n = 6, respectively). Another six nHA-PA 66 scaffolds
were used for ultrastructure evaluation based on scanning
electron microscopy (SEM) to observe the micro-
architecture. To adapt to AV-bundle embedding in vivo, a
side groove was made that passed through the scaffold
along its long axis.
rADSCs isolation and cultivation
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
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The protocol was approved by the Committee on the
Ethics of Animal Experiments of the Xi’an Jiaotong
University.
An aseptic cut of Sprague Dawley (SD) rat adipose tis-
sue was performed, and adipose-derived stem cells were
extracted in accordance with the conventional method
[28]. The third passage of rADSCs (P3 rADSCs) were
obtained for evaluating the multilineage differentiation
capacity after flow cytometry confirmation.
Flow cytometry
Briefly, P3 rADSCs were trypsinized and incubated with
fluorescein conjugated antibody against CD29, CD34,
CD44 and CD45 (Santa Cruz, CA, USA) at 4°C in 0.5%
BSA and 2 mM EDTA in PBS for 30 min. Subsequently,
the labeled cells were run on a BD FACSCanto II flow
cytometer (BD, CA, USA) to identify the phenotypes.
Osteogenic induction and adipogenic induction
Osteogenic induction experiments were conducted using
previous methods with minor modifications [29]. At week
2 of culture, alkaline phosphatase (ALP) calcium cobalt
staining was conducted, and at week 4 of culture, alizarin
red staining was conducted. Adipogenic induction experi-
ments were also carried out according to the methods pre-
viously described [29], and Oil Red O staining was used to
confirm the inductive efficiency.
Endothelial differentiation and confirmation
P3 rADSCs were suspended in endothelial differentiation
medium (medium 199 + 50 ng/ml VEGF + 10 ng/ml
b-FGF + 3% FBS) at a density of 1 × 105/ml and 0.5 ml of
cell suspension was added to each well of a 12-well plate.
Cultures were incubated at 37°C in a 5% CO2. The medium
was changed 3 times for 8 days. Differentiation was con-
firmed by angiogenesis assay and immunocytochemistry.
Angiogenesis assay
After rADSCs were differentiated with endothelial differ-
entiation medium for 8 days, the cells were trypsinized
and seeded a 24-well plate which was coated with Matrigel
(8.8 mg/ml; BD,USA) at a concentration of 5 × 104/well in
endothelial differentiation medium. Cultures were incu-
bated at 37°C in a 5% CO2 humidified atmosphere for
48 h and observed with an inverted photomicroscope.
Western blot analysis for von willebrand factor expression
After rADSCs were differentiated with endothelial differ-
entiation medium for 8 days, the cells were trypsinized
and the proteins were also prepared for western blot assay
of von Willebrand factor [(rabbit anti-rat vWF polycolonal
antibody, Santa Cruz, CA, USA)] as described previously
[30]. Mouse anti-rat β-actin (Sigma, MO, USA) antibodywas used as internal control gene. The un-differentiated
P3 rADSCs were used as control group.
In vitro construction of rADSCs-Endo/nHA-PA 66 scaffold
composites and rADSCs/nHA-PA 66 scaffold composites
After rADSCs were differentiated with endothelial differ-
entiation medium for 8 days (termed as rADSC-Endo),
the density of the rADSCs-Endo cells were adjusted to
2 × 104/mL and the cells were seeded into the scaffolds
with 1 ml in each (termed as rADSCs-Endo/nHA-PA 66
scaffold composite, n = 28). Two rADSCs-Endo/nHA-PA
66 scaffold composites were removed respectively at 3 and
7d during co-culturing, and after conventional treatment,
SEM was use to evaluate the composite structure of cells
and scaffolds. The composites prepared using the same
methods with a substitution of P3 rADSCs for rADSCs-
Endo cells were termed rADSCs/nHA-PA 66 scaffold
composites (n = 24).
In vivo experiments
Animals and study groups
96 SD rats (male, weighing 350–450 g) were used and
assigned randomly into 4 groups according to the different
composites used. Prior to experimentation, all rats were
housed in a temperature-controlled room under a 12 hr/
12 hr-light/dark and were allowed access to standard rat
chow and tap water ad libitum. All surgical procedures
were conducted under aseptic conditions and general
anesthesia (pentobarbital, 30 mg/kg).
Surgical procedures
Through a 2 cm skin incision parallel to the left inguinal
ligament, the soft tissues around the inferior epigastric ar-
tery and vein were carefully removed, and the AV-bundle
was fully exposed. For Group A (n = 24), the AV-bundle
was inserted into the side groove of the rADSCs-Endo/
nHA-PA 66 scaffold composite and fixed with surround-
ing tissue. A schematic outline of the surgical procedures
was shown in Figure 1. For Group B and Group C (n = 24,
respectively), the AV-bundle was inserted into the side
groove of the rADSCs/nHA-PA 66 scaffold composite and
nHA-PA 66 scaffold respectively. For Group D (n = 24),
the nHA-/PA 66 scaffold was directly embedded into
quadriceps without AV-bundle.
Incisions were then closed with a 1–0 fiber thread su-
ture line in a routine fashion. The animals were monitored
post-operatively. At 2 and 4 weeks after surgery, twelve
rats from each group were sacrificed under general
anesthesia (n = 6 for histological evaluation and western
blot assay, respectively). Blood vessels were broken and
the implants were removed in Group A, B and C. All the
samples were fixed with 4% paraformaldehyde for 24 h.
After full decalcification with 20% EDTA, histological and
immunohistochemical staining was conducted.
Figure 1 Schematic diagrams (A: longitudinal view; B: trasversial view) demonstrate the relationship between C-shape nHA/PA66
scaffold and the implanted AV-bundle. A: implanted artery; V: implanted vein.
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At 2 and 4 weeks postoperatively (n = 6 for each group),
the implants with the surrounding tissues were retrieved.
The samples were cut into 8-μm sections and stained with
Masson-trichrome staining for histological evaluation.
The conventional method was employed for vWF im-
munohistochemical staining [31]. The degree of scaffold
vascularization was observed under upright microscope
in 200× or 400× amplification field.
Histological quantitative analysis
A light microscope (Leica, Germany) was used for histo-
logical evaluation. 6 transverse serial sections in the central
parts of the scaffolds were used for histomorphometrical
evaluation using computer-based image analysis techniques
(Leica Qwin Pro-image analysis system, Germany). The
following parameters were determined by digital analysis
in a blinded manner.
1. Vessel density [32]. For Masson trichrome stained
sections, structures were identified as vessels if they
met two of the three following criteria: the presence
of an endothelial cell lining, a well-defined lumen
and the presence of red blood cells. In sections la-
beled with vWF, the structures that were stained
brown and had a well-defined lumen were counted
as blood vessels. The number of vessels in the sec-
tion was counted manually at 200× magnification,
and the vessel density was represent as the number
of vessels/mm2.
2. Vessel diameter [32]. For each vessel, the least
diameter, i.e. the two diametrically opposed points
on the luminal microvessel wall, was identified at
400× magnification.
In vivo VEGF-C, fibroblast growth factor 2 (FGF-2) and
bone morphogenetic protein 2 (BMP-2) protein expres-
sion detection by western blot analysis
After retrieval from the rats, the implants (n = 6 for each
group at 2 and 4 weeks, respectively) were extensively
washed with PBS and placed in a pre-cooled mortar and
was ground within the liquid nitrogen for protein extrac-
tion. Total 50 μg proteins were loaded for electrophoresison SDS-polyacrylamide gel, and then transferred to PVDF
membranes. Rabbit anti-rat VEGF-C polyclonal antibody,
rabbit anti-rat FGF-2 polyclonal antibody and rabbit anti-
rat BMP-2 polyclonal antibody (Santa Cruz, CA, USA)
were diluted at a concentration of 1:500, 1:200 and 1:100
respectively. The working concentration of internal con-
trol mouse anti-rat β-actin monoclonal antibody (Sigma,
MO, USA) was 1:2000. The antibodies were incubated at
4°C for overnight. The membranes were then incubated
with horseradish peroxidase labeled anti-rabbit IgG (for
detection of VEGF-C, FGF-2 and BMP-2) and anti-mouse
IgG (for detection of β-actin) with the dilution of 1:500 at
room temperature for 2 h. The protein bands were visual-
ized by DAB staining. The ratio of the intensities of the
target genes and β-actin bands was used to represent the
level of the target gene protein expression.
Statistical analysis
SPSS11.0 statistical software was used for analysis. The
data were expressed as mean ± standard deviation. The
analysis of variance (ANOVA) was used for group com-
parison, and post hoc test was used for pairwise compari-
son (inspection level α = 0.05).
Results
In Vitro experiments
The characteristic of the nHA-PA 66 scaffold
The biomechanical property including elastic modulus,
bending strength and compressive strength were shown
in Table 1, which were similar to those of the natural
bone [33]. Under gross view, the scaffold exhibited a cy-
lindrical type with the diameter of bottom surface as
4.0 mm and the height as 20 mm (Figure 2A). It was
found that the material exhibited a porous surface, and
there were interconnections between macropores. Under
higher magnification, macropore exhibited smooth walls
(Figure 2B-2D). The porosity was (68.41 ± 9.20) %,
macropore size was (620.16 ± 111.85) μm and intercon-
nection pore size was (185.41 ± 84.25) μm; these param-
eters were in accordance with previously reported [26].
To adapt to vascular bundle embedding, a side groove
(width: 2.0 mm) which passed through the scaffold along
its long axis was made in each of the scaffolds.
Table 1 Physical properties of the porous nHA/PA66 scaffold
Porosity
(%)
Macropore diameter
(μm)
Interconnection diameter
(μm)
Elastic modulus
(Gpa)
Bending strength
(Mpa)
Compressive strength
(Mpa)
68.41 ± 9.20 620.16 ± 111.85 185.41 ± 84.25 6.25 ± 0.82 85.14 ± 12.13 100.12 ± 18.95
3-25* 90-95* 110-125*
*indicate to nature bone.
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adipogenic induction observation
rADSCs exhibited the morphology of fibroblastoid mono-
nuclear cells (Figure 3A). After osteogenic induction,
ALP activity and mineralized matrix deposition were
confirmed by ALP staining (Figure 3B) and alizarin red
staining (Figure 3C). Oil Red O staining after adipogenic
induction was performed to detect lipid accumulation.
Many orange-red lipid droplets of different sizes were
seen in the cytoplasm; additionally, there were droplets
that accounted for 80% to 90% of the entire cell volume
(Figure 3D).
Flow cytometry
Flow cytometry demonstrated that the cultured P3 rADSCs
were positive for CD29 and CD44 but negative for CD34
and CD45 (Figure 4A-D). The phenotypes were in accord-
ance with those reported by Xu YF et al. [34].
Endothelial differentiation and confirmation
After rADSCs were differentiated with endothelial dif-
ferentiation medium for 8 days, the cells were trypsi-
nized and seeded in a 24-well plate coated with Matrigel
for angiogenesis assay (Figure 5A). During the first 24 h,
cells spread randomly, moved, and started to form small
and seldom interconnected clusters (Figure 5B). At 48 h,Figure 2 Gross view (A) and SEM photomicrograph of the nHA-PA66
scaffold. D: Higher magnification showed the wall of the macropores. P, poclusters increased in size and were highly connected,
discrete Matrigel areas were empty and surrounded by cell
islets or chains (Figure 5C). Based on western blot ana-
lysis, the protein expression of vWF was also detected
after rADSCs were differentiated with endothelial differen-
tiation medium for 8 days (Figure 5D).In vitro construction and testing of rADSCs-Endo/nHA-PA 66
scaffold composites
At 3d after co-culturing of rADSCs-Endo cells and the
scaffolds, the number of the cells in the scaffolds re-
duced, while cell morphology was not fully extended
with a small amount of matrix secretion (Figure 6A); At
7d, the number of the cells significantly increased, and
the morphology was fully extended and long fusiform
(Figure 6B).In vivo experiments
Clinical and physical examinations
95 of 96 rats survived over the time course of the study;
one rat of group B was died during anesthesia, and severe
infection was noted in one rat in group B. Therefore, two
additional rats were operated on to maintain the experi-
mental design numbers (total number of rats, 98).scaffold (B, C and D). B, C: Lower magnification of the surface of the
re; I, interconnecting path.
Figure 3 Examination of rADSCs differentiation capacity into osteogenic and adipogenic lineages. A: P3 rADSCs. B and C: cells were
positive for alkaline phosphatase staining and alizarin red staining after osteogenic induction. D: cells were positive for oil red staining after
adipogenic induction, indicating they differentiated into mature adipocytes. Bars indicate 100 μm.
Figure 4 Flow cytometry analysis of rADSCs. P3 rADSCs are CD34 and CD45 negative (B and D), but CD29 and CD44 positive (A and C).
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Figure 5 Angiogenesis assay. After rADSCs were differentiated in endothelial differentiation medium for 8 days, the differentiated cells were
placed in Matrigel in a 24-well plate. A: 1 hour after cell-seeding; B: 24 hours after seeding, exhibit partial tubule formation, C: 48 hours after cell
seeding, clearly demonstrated capillary-like networks between cells. D: Western blot analysis using anti-vWF revealed up-regulation of vWF in
rADSCs-Endo group. Bars indicate 100 μm.
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At 2 and 4 weeks after surgery, the Masson’s trichromes-
tained sections from each group showed that the scaffolds
were in-grown together with fibrous connective tissues
and blood vessels. In group A, B and C, when the scaffolds
were retrieved at both 2 and 4 weeks, noticeable bleeding
occurred due to the implanted AV-bundle, which indi-
cated the vessels did not blockage by the thrombosis
in vivo. In group D, the samples were encapsulated with
fibrous tissue.
Histologically, at 2 weeks after surgery in Group A, B
and C, newly formed vessels were prominent in the AV-
bundle and the adjacent tissue, but the diameter of newly
formed vessels was small. At 4 weeks in Group A the
number of newly formed vessels significantly increasedFigure 6 SEM photomicrograph of rADSC/nHA-PA 66 scaffold compo
C, rADSCs-Endo cells.around the implanted AV-bundle, and the diameter was
larger. Small arteries were also observed in Group A but
not in Group B and C. While only some immature capil-
laries were observed in Group D (Figures 7 and 8). Gener-
ally, luminal sprouting from the inferior epigastric vein
was observed in group A at 4 weeks. In all groups, osteoid
and osteoblast were not observed both at 2 or 4 weeks
after surgery.
Histological quantitative analysis
At 2 weeks after surgery, the vessel density in Group A
(78.31 ± 8.25)/mm2 was significantly higher than Group
B and C [(48.72 ± 8.73)/mm2 and (46.03 ± 3.97)/mm2]
(both p<0.05). Both Group A, B and C were significantly
higher than group D (31.04 ± 6.54)/mm2 (p<0.05). Atsite. A: At 3 days after seeding. B: At 7 days after cell seeding.
Figure 7 Histological observation of the scaffolds of group A, B, C and D at 2 and 4 weeks after implantation. Masson trichrome stain.
A: implanted artery; V: implanted vein; N: neovessels; S: residual scaffold. Bold arrow indicates the luminal sprouting from the vein. Bars indicate
500 μm.
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mm2 were also higher than that of Group B and C
[(82.02 ± 9.17)/mm2 and (79.28 ± 5.57)/mm2] (both p<0.05).
Again, Group A, B and C were also significantly higher
than group D (61.02 ± 8.74)/mm2 (both p<0.05). Signifi-
cant difference was also presented in group A at 2 weeks
vs Group A at 4 weeks (p<0.05), the same trends were also
observed in group B, C and D. Between Group B and C,
no statistical differences were observed at each time point
for vessel density (Figure 9A).
The vessel diameter at 2 weeks in Group A [(56.87 ±
3.45) μm] was larger than that in Group B [(25.94± 4.27) μm],
Group C [(25.71 ± 10.12) μm] and Group D [(8.12 ± 3.08 μm]
(both p<0.05). At 4 week after surgery, the vessel
diameter in Group A [(85.20 ± 12.88) μm] was still
larger than that in Group B [(57.02 ± 6.30) μm], Group C
[(55.28 ± 7.25) μm] and Group D [(12.87 ± 9.68) μm]
(both p<0.05). Significant differences were also observed
within all of the groups at the two time points. Reflectiveof vessel density, no statistical differences were observed
between Group B and C at each time point for vessel
diameter (Figure 9B).VEGF-C, FGF-2 and BMP-2 protein expression analysis
We further confirmed the expression pattern of VEGF-C,
FGF-2 and BMP-2 in vivo by western blot in each group
at different time points post-surgery. As demonstrated in
Figure 10, there was dramatically higher expression of
VEGF-C and FGF-2 protein in Group A than the other
three groups at 2 or 4 weeks (both p<0.05). Statistical dif-
ferences were observed on the expression of VEGF-C and
FGF-2 protein at each time point between Group B and D
or Group C and D (both p<0.05). Statistical differences
were not observed in VEGF-C and FGF-2 expression be-
tween Group B and C in each time point (both p<0.05).
BMP-2 was not expressed in each group at each time
point (Additional file 1: Figure S1).
Figure 8 Typical immunohistochemical images for vessels of vWF antibody of group A, B, C and D at 2 and 4 weeks after implantation
(brown staining). Bars indicate 500 μm.
Figure 9 Vessel density (A), vessel diameter (B) analysis of each group at 2 and 4 weeks after implantation. * indicates compared with
Group C at the same time point, p > 0.05.
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Figure 10 Western blot results of VEGF-C and FGF-2 of each group at 2 and 4 weeks demonstrated increased protein expression in
Group A. * indicates compared with Group C at the same time point, p > 0.05.
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In the present study, we successfully constructed a novel
tissue engineered construct by using pre-differentiated
rADSCs (endothelial differentiation) and porous nHA-PA
66 scaffold in vitro. Subsequently, the inferior epigastric
AV-bundle was directly clipped in the composite for
evaluating its capability of angiogenesis in vivo. The results
revealed that compared with muscular wrapping method,
AV-bundle implantation could promote vascularization of
the scaffold; and the angiogenesis of the scaffold was sig-
nificantly accelerated when pre-differentiated rADSCs
(endothelial differentiation) were added. These positive re-
sults implicate the combination of pre-differentiated
rADSCs (endothelial differentiation) and AV-bundle may
achieve rapidly angiogenesis for biomaterial scaffold.
Tissue-engineered bone without intrinsic vascular net-
work is recognized as “dead bone”. The process of revas-
cularization in vivo usually requires a long period of time,
and implanted bone necrosis and trauma non-union may
occur, which is suggested to be caused by cell death of
area farther from the capillaries [35]. Generally, the distri-
bution of cells is limited to a distance of 150–200 μm away
from the nearest capillary which is the effective diffusion
range of nutrients and oxygen [36,37]. Therefore, assembly
of a vascular network with the necessary vessel toexchange oxygen and nutrients to cells within the scaffold
is crucial for the survival of cells and healing efficacy of
the tissue engineered graft after implantation in vivo.
In 1993, Mikos et al. initiated the concept of pre-
vascularized tissue engineered grafts based on the different
performance of pre-vascularized and non-vascularized
scaffolds in vivo [38]. The vascular system inside the bone
tissue not only enhances the survival of bone tissue cells,
but also produces growth cytokines and mesenchymal
stem cells to promote bone metabolism and repair. Fur-
thermore, abundant blood supply may prevent infection
[10,13-15,36-38]. Many researches have been focused on
prefabrication of vascular network in vitro. While after the
in vitro prefabricated graft with capillary network has been
implanted in vivo, the vascular anastomosis between the
host vessels and the prefabricated capillaries could not be
achieved within a short period due to the limitation of
host vascular ingrowth rate of several tenths of microme-
ters per day [39].
Recent studies have demonstrated that axial vascula-
rization in engineered grafts could be prefabricated in vivo
using the pre-existing vessels, thus accelerating the repair
of bone injury, so called “in vivo bioreactor” technique
[10-17]. As for the pre-existing vessels, several studies
confirmed that AV-loop could effectively accelerate the
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this technique, femoral artery-vein and saphenous artery-
vein models were the most widely used to construct the
AV-loop. Unfortunately, the technique destroys the blood
supply at donor site, which is needed for adequate pro-
gression of arteriovenous anastomosis. AV-bundle is
another choice to prefabricate the vascularized graft
[15,17,40]. Some scholars have used thoracodorsal AV-
bundle, femoral AV-bundle, deep femoral AV-bundle
and saphenous AV-bundle as an “in vivo bioreactor” to
construct the pre-vascularized grafts successfully.
In this study, inferior epigastric AV-bundle were
adopted based on the merits such as superficial anatomical
location and adequate length. More importantly, it is con-
sidered to be a nonfunctional vessel. As engineered bone
vascular network sources, inferior epigastric AV-bundle
will not cause major damage to body functions and will
meet the body’s need for bone tissue engineering. Further-
more, Tanaka Y et al. [10] demonstrated that flow-through
type (distal un-ligated AV-bundle) enhanced angiogenesis
but was weaker than ligation type (distal ligated AV-
bundle). In the present study, the inferior epigastric AV-
bundle was left un-ligated because of the increased risk of
thrombosis of the ligation type which would affect the
efficiency of the transportation nutrients and oxygen
after anastomosis at the receptor site. In our experiment,
the results demonstrated that abundant new capillaries
were observed around the AV-bundle compared with the
muscle encapsulated type.
In addition to the pre-existing vessel approach to in-
crease the vascularization efficiency of engineered con-
structs, several techniques have supplemented angiogenic
growth cytokines and cells. Undoubtedly, angiogenic cyto-
kines such as VEGF and FGF could improve endothelial
cell proliferation, cell migration, tube formation, and func-
tional blood vessel formation both in vitro and in vivo
[41-45]. However, because of their short biological half life,
long-lasting and controlled-release delivery systems still
remains a challenge. Cells that can secrete angiogenic
cytokines could partially solve the problem. Bleiziffer O
et al. [20] seeded endothelial progenitor cells (EPCs) into
bioartificial matrices together with the AV-loop, demon-
strating that EPCs may hold promise to modulate blood
vessel formation. Rouwkema J et al. [21] reported that hu-
man umbilical vein endothelial cells (HUVECs) are able to
form a three-dimensional prevascular network in vitro in
a bone tissue engineering. Unfortunately, the limited
sources of EPCs and HUVECs have hampered their wide
applications, which lead us to find another suitable cell
candidate for the prefabrication of vascularized grafts.
To date, stem cell based tissue engineering is focused
on BMSCs. Despite the controversies, some scholars
have described that there are no differences on multili-
neage differentiation capacities between BMSCs andADSCs [46,47]. Recently, ADSCs have been successfully
and reliably differentiated into an endothelial cell
lineage [22,48,49]. ADSCs are easier to obtain than
BMSCs, have lower donor-site morbidity, and are avail-
able in larger numbers. In addition, the isolation efficacy
of ADSCs does not change with advanced age, gender,
obesity, renal failure or vascular disease [50]. ADSCs
provide a clear advantage as an alternative source for
endothelial cells. Many scholars reported that endothelial
cells in different origin (adipose tissue, bone marrow, um-
bilical vein, or peripheral blood) have the similar capacity
to accelerate the process of angiogenesis in tissue engi-
neered implants in the absence of exogenous angiogenesis
growth factors [51-53].
Angiogenesis is modulated through complex molecular
signals mediated by various cytokines involving extracellu-
lar matrix remodeling, endothelial cells proliferation and
migration, capillary differentiation and anastomosis. VEGF
and FGF are vital angiogenic cytokines based on their cap-
acities of regulating the budding and growth of new ves-
sels from existing vessels [54]. They are predominantly
produced in tissues that acquire new capillary networks
[55]. In the present study, the highly expressed of VEGF-C
and FGF-2 were detected in Group A compared to the
other 3 groups at each time point based on our in vivo
western blot assay. This was contributed to autocrine
VEGF and FGF-2 from endothelial cells. Increased expres-
sion of VEGF and FGF-2 may promote the physiologic
function of the endothelial cells. As anticipated, luminal
sprouting from the inferior epigastric vein was observed at
a faster rate than the other three groups. Particularly in
Group B, vessel diameter, vessel density, VEGF and FGF-2
protein expression were found to be slightly higher than
group C, but no statistical difference was observed. This
may be attributed to the deficient number of rADSCs and
the absence of the endothelial differentiated conditions
in vivo.
The study of cell-scaffold or growth factor-scaffold
composites in vitro and induced tissue and organ regen-
eration in vivo have been advanced by the development
and extensive use three-dimensional porous biomaterials
scaffold. Microarchitectures such as porosity, macropore
shape, macropore size, and interconnections are critical
characteristics to improve the efficiency the scaffolds
[56,57] Macropores and interconnections between nearby
macropores act as two constitutive components of scaf-
folds, which strongly influence cell migration and tissue
penetration [56-58]. As previously reported, macropore
size larger than 400 μm is facilitated for the progression of
not only osteogenesis but also angiogenesis and suitable
for bone tissue engineering application [59]. Furthermore,
interconnections with the size of larger than 100 μm can
facilitate mineralized bone tissue ingrowth and 5–15 μm
for fibrous tissue [59].
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rials to construct the scaffold. The nHA-PA 66 composite
which compounds inorganic material nHA and organic
polymer material PA 66 dramatically resembles natural
bone in its composition, structure, and mechanical prop-
erties (elastic modulus, bending strength and compressive
strength), which is responsible for its good biocompatibil-
ity, osteoconductivity, and bioactivity [24-26]. Further-
more, the porosity, macropore size and interconnection
pore size were also in accordance with the preferred pa-
rameters for bone tissue engineering scaffold. Compared
with sole HA biomaterials, partially biodegradation could
be observed of the nHA-PA 66 scaffold at 4 weeks after
implantation by the presence of organic biomaterials
(PA 66), which may result in more newly formed tissue
ingrowth [38].
In all groups, osteoid and osteoblast could not be ob-
served based at 2 or 4 weeks after surgery. Our in vivo
western blot confirmed that no BMP-2 protein was de-
tected. The possible reasons may be that: (1) The nHA-
PA 66 scaffold we adopted was not the osteoinductive
biomaterials; (2) In group A, C and D, bone progenitor
cells may not present in the operative areas, which are
crucial for osteogenesis; (3) In group B, local environ-
ment at the operative region could not promote the
osteogenic differeation of ADSCs. In the subsequently
experiments, we focused on the co-cultured rADSCs-endo
cells and osteoblasts together with porous scaffolds and
the AV-bundle in order to prefabricate osseous construct
with axial vessels simultaneously.
Conclusion
In summary, compared with simply AV-bundle implant-
ation and muscular wrapping method, the combination of
pre-differentiated rADSCs (endothelial differentiation) and
AV-bundle will achieve rapidly angiogenesis of biomaterial
scaffold.
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